Du Toit D F, Heydenrych J J, Smit B, Louw G, Zuurmond T, Els D, Du Toit L B, Weideman A, Davids H, van der Merwe E
Transplantation. 1987 Sep;44(3):346-50. doi: 10.1097/00007890-198709000-00004.
The prolongation of segmental and pancreaticoduodenal allografts (PDA) by total lymphoid irradiation (TLI) and in combination with cyclosporine (CsA) was assessed in a well established total pancreatectomy, diabetic, primate transplantation model. Pancreatic transplantation was performed in 119 pancreatectomized baboons (Papio ursinus). Of a total of 109 allografts performed, 71 were segmental allografts (open duct drainage) and 38 PDA. Of 119 graft recipients, 10 received segmental pancreatic autografts. TLI and CsA administered separately to segmental allograft recipients resulted in modest allograft survival and indefinite graft survival was not observed. 8 of 17 (47%) segmental allograft recipients that received TLI and CsA had graft survival beyond 100 days, indicating highly significant pancreatic allograft survival. All long-term segmental allograft recipients were rendered normoglycemic (plasma glucose less than 8 mmol/L) by this immunosuppressive regimen. In contrast, poor results were observed in PDA recipients treated with TLI and CsA. Mean survival in 18 treated PDA recipients was 23.8 days, 8 survived longer than 20 days (44.4%), and 1 greater than 100 days (5.5%). Despite treatment, early rejection of the duodenum in PDA recipients frequently resulted in necrosis and perforation and contributed to a high morbidity and mortality. This study indicates that, in contrast to the significant prolongation of segmental allografts by TLI and CsA, poor immunosuppression was achieved by this regimen in PDA recipients and was associated with a high morbidity and mortality caused by early rejection of the duodenum.
在一个成熟的全胰切除术、糖尿病灵长类动物移植模型中,评估了全身淋巴照射(TLI)联合环孢素(CsA)对节段性和胰十二指肠同种异体移植(PDA)的延长作用。对119只接受全胰切除术的狒狒(豚尾狒狒)进行了胰腺移植。在总共109例同种异体移植中,71例为节段性同种异体移植(开放导管引流),38例为PDA。在119例移植受者中,10例接受了节段性胰腺自体移植。对节段性同种异体移植受者单独给予TLI和CsA,导致同种异体移植存活时间适度,未观察到移植长期存活。17例接受TLI和CsA的节段性同种异体移植受者中有8例(47%)移植存活超过100天,表明胰腺同种异体移植存活具有高度显著性。通过这种免疫抑制方案,所有长期节段性同种异体移植受者均实现血糖正常(血浆葡萄糖低于8 mmol/L)。相比之下,接受TLI和CsA治疗的PDA受者结果不佳。18例接受治疗的PDA受者的平均存活时间为23.8天,8例存活超过20天(44.4%),1例超过100天(5.5%)。尽管进行了治疗,PDA受者十二指肠的早期排斥反应经常导致坏死和穿孔,并导致高发病率和死亡率。这项研究表明,与TLI和CsA显著延长节段性同种异体移植存活时间相反,该方案在PDA受者中免疫抑制效果不佳,且与十二指肠早期排斥反应导致的高发病率和死亡率相关。